Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetic Nephropathy01:28

Diabetic Nephropathy

28
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
28
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

1.1K
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Long-term Comparisons of Rituximab versus Calcineurin Inhibitors for Membranous Nephropathy in the Cure Glomerulonephropathy Study.

Kidney360·2026
Same author

The podocyte slit-diaphragm: target of anti-nephrin antibodies.

Current opinion in nephrology and hypertension·2026
Same author

Circulating Testican-2 and MGT5A are Markers of Membranous Nephropathy.

Kidney international reports·2026
Same author

Rapid podocyte loss in murine models triggers the formation of podocyte-parietal epithelial cell intercellular bridges.

American journal of physiology. Renal physiology·2026
Same author

Associations of Podocyte-Derived Protein Biomarkers With Foot Process Effacement and Kidney Histopathologic Lesions in Individuals With Glomerular Disease.

Kidney medicine·2025
Same author

<i>Fosl2</i> regulates the transition from parietal epithelial cells to myofibroblasts in the kidney.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Apr 28, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.1K

Membranous nephropathy: from models to man.

Laurence H Beck, David J Salant

    The Journal of Clinical Investigation
    |June 4, 2014
    PubMed
    Summary

    Membranous nephropathy (MN) is an autoimmune kidney disease targeting glomerular podocytes. Identifying the phospholipase A2 receptor 1 (PLA2R) as the key antigen advances diagnosis and potential therapies for this cause of nephrotic syndrome.

    Area of Science:

    • Nephrology
    • Immunology
    • Pathology

    Background:

    • Primary membranous nephropathy (MN) was historically considered idiopathic, a common cause of nephrotic syndrome in adults.
    • Recent understanding identifies MN as an organ-specific autoimmune disease.
    • Autoantibodies target intrinsic antigens on glomerular podocytes, forming immune complex deposits.

    Purpose of the Study:

    • To define the clinical and pathological features of membranous nephropathy (MN).
    • To describe experimental models leading to the identification of the M-type phospholipase A2 receptor 1 (PLA2R) as the major target antigen.
    • To review the pathophysiology of experimental and human MN and discuss diagnostic strategies.

    Main Methods:

    • Review of clinical and pathological features of MN.

    More Related Videos

    A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
    07:52

    A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

    Published on: November 7, 2017

    20.5K
    A Murine Model of Hemodialysis Access-Related Hand Dysfunction
    08:39

    A Murine Model of Hemodialysis Access-Related Hand Dysfunction

    Published on: May 31, 2022

    1.8K

    Related Experiment Videos

    Last Updated: Apr 28, 2026

    Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
    07:15

    Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

    Published on: August 23, 2024

    1.1K
    A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
    07:52

    A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

    Published on: November 7, 2017

    20.5K
    A Murine Model of Hemodialysis Access-Related Hand Dysfunction
    08:39

    A Murine Model of Hemodialysis Access-Related Hand Dysfunction

    Published on: May 31, 2022

    1.8K
  • Description of experimental models for MN antigen discovery.
  • Analysis of diagnostic utility of serological testing for anti-PLA2R antibodies and tissue antigen staining.

    • Main Results:

    • The M-type phospholipase A2 receptor 1 (PLA2R) is identified as the primary target antigen in MN.
    • Experimental models have elucidated the pathophysiology of MN.
    • Serological and tissue-based tests for anti-PLA2R are valuable for diagnosis and differentiation.

    Conclusions:

    • Membranous nephropathy (MN) is an autoimmune disease driven by autoantibodies against PLA2R on podocytes.
    • Diagnostic tools like anti-PLA2R testing aid in differentiating primary, secondary, recurrent, and de novo MN.
    • Understanding the PLA2R antigen offers potential for future therapeutic strategies.